Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 43-48

  Chen, Jiong ^a   Wu, Wen ^a   Zhen, Chunsheng ^a   Zhou, Hangchen ^a   Yang, Renbao ^a   Chen, Longjiang ^a   Hu, Liwei ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Apolipoprotein E; Complement C3; Complement C4b1; Pancreatic cancer

Indexed keywords

APOLIPOPROTEIN E; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PANCREAS CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84878312615     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1326     Document Type: Article

References (26)

1. Guo X and Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31: 13-22, 2005.
2. Willett CG, Daly WJ and Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352, 1996.
3. Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270, 2007.
4. Marrelli D, Caruso S, Pedrazzani C, et al: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 198: 333-339, 2009.
5. Grønborg M, Bunkenborg J, Kristiansen TZ, et al: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3: 1042-1055, 2004.
6. Cecconi D, Palmieri M and Donadelli M: Proteomics in pancreatic cancer research. Proteomics 11: 816-828, 2011.
7. Hugli TE: Structure and function of the anaphylatoxins. Springer Semin Immunopathol 7: 193-219, 1984.
8. Scholz W, McClurg MR, Cardenas GJ, et al: C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 57: 297-307, 1990.
9. Wang W, Abbruzzese JL, Evans DB, et al: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999.
10. Habermann JK, Roblick UJ, Luke BT, et al: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131: 1020-1029, 2006.
11. Pickering MC, Botto M, Taylor PR, et al: Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76: 227-324, 2000.
12. Einav S, Pozdnyakova OO, Ma M and Carroll MC: Complement C4 is protective for lupus disease independent of C3. J Immunol 168: 1036-1041, 2002.
13. Fujita T, Hara A and Yamazaki Y: The value of acute-phase protein measurements after curative gastric cancer surgery. Arch Surg 134: 73-75, 1999.
14. Greenow K, Pearce NJ and Ramji DP: The key role of apolipoprotein E in atherosclerosis. J Mol Med (Berl) 83: 329-342, 2005.
15. Trompet S, Jukema JW, Katan MB, et al: Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 170: 1415-1421, 2009.
16. Trost Z, Marc J, Sok M and Cerne D: Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients. Arch Med Res 39: 663-667, 2008.
17. Grant WB: A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor. Anticancer Res 30: 189-199, 2010.
18. Andreotti G, Chen J, Gao YT, et al: Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17: 525-534, 2008.
19. Moore LE, Brennan P, Karami S, et al: Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res 69: 8001-8008, 2009.
20. Beppu T, Gil-Bernabe P, Boveda-Ruiz D, et al. High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice. J Tromb Haemost 8: 2514-2522, 2010.
21. Mrkonjic M, Chappell E, Pethe VV, et al: Association of apolipoprotein E polymorphisms and dietary factors in colorectal cancer. Br J Cancer 100: 1966-1974, 2009.
22. Grønborg M, Kristiansen TZ, Iwahori A, et al: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171, 2006.
23. Yu KH, Rustgi AK and Blair IA: Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 4: 1742-1751, 2005.
24. Gillard BK, Lin HY, Massey JB and Pownall HJ: Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta 1791: 1125-1132, 2009.
25. Huvila J, Brandt A, Rojas CR, et al: Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors. Int J Gynecol Cancer 19: 1226-1231, 2009.
26. Martínez-Clemente M, Ferré N, González-Périz A, et al: 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 51: 817-827, 2010.